<DOC>
	<DOCNO>NCT02451007</DOCNO>
	<brief_summary>Study assess potential effect lurbinectedin ( PM01183 ) therapeutic dose duration QTc interval , measure electrocardiogram ( ECGs ) , characterize PM01183 plasma concentration/QTc relationship , explore related ECG parameter patient select solid tumor .</brief_summary>
	<brief_title>Evaluation Effect Lurbinectedin ( PM01183 ) Cardiac Repolarization Patients With Selected Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Voluntarily sign date informed consent Normal cardiac conduction function ( centrally read ) Blood pressure 90 150 mmHg systolic , inclusive , high 90 mmHg diastolic . Specific serum electrolyte level Age &gt; 65 year Performance status = 2 [ Eastern Cooperative Oncology Group ( ECOG ) ] Heart rhythm disturbance Significant ischemic coronary disease , heart failure , myocardial infarction , unstable angina within last six month . Prior exposure anthracyclines cumulative dose doxorubicin ( equivalent ) &gt; 450 mg/mÂ²</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>